Table 5. Safety- Adverse Events (AEs) of Rintatolimod (PolyI:C₁₂U).

	Rintatolimod (n =  117)		Placebo (n = 117)
A. Stage 1: AEs During 40 Weeks of Drug Exposure	Number of Patients	% of Patients	Number of Patients	% of Patients
Patients with ≥1 AE	116	99.1	113	96.6
All AEs with p≤0.05
Flu-like syndrome	62	53.0	46	39.3
Chills	26	22.2	11	9.4
Vasodilatation	25	21.0	11	9.4
Dyspnea	14	12.0	4	3.4
Patients with ≥1 Serious AE	12	10	6	5